1 – 3 of 3
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
(
- Contribution to journal › Article
- 2019
-
Mark
Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study) : Protocol for a multicenter phase II open label study
(
- Contribution to journal › Article
- 2016
-
Mark
Cancer differentiating agent hexamethylene bisacetamide inhibits BET bromodomain proteins
(
- Contribution to journal › Article